Secukinumab
- PDF / 170,360 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 50 Downloads / 160 Views
1 S
Autoimmune haemolytic anaemia: case report A 66-year-old woman developed autoimmune haemolytic anaemia (AIHA) during treatment with secukinumab for psoriatic arthritis. The woman, who had a history of psoriatic arthritis, started receiving secukinumab after the slow response of TNF-α inhibitors. She received a loading dose of 300 mg on four different weeks, followed by 300 mg in an interval of 4 weeks [route not stated]. Her blood cell count was regularly performed. Her concomitant medication included paracetamol [acetaminophen] and codeine. After four months of treatment with secukinumab, she experienced shortness of breath, weight loss and asthenia. Reports of blood cell count showed depletion of haemoglobin concentration, haematocrit 30%, unconjugated bilirubin 12.1 µmoL/L, lactate dehydrogenase 321 UI/L and haptoglobin level was undetected. The direct anti-globulin test (DAT) was positive for anti-IgG and anti-C3, but there was no renal impairment and viral infection. Along with this, there were no antinuclear antibodies found, as well as there was no iron or vitamin deficiency noted. The woman’s secukinumab therapy was discontinuation, and her symptoms improved gradually. Reports of DAT were found negative, and secukinumab induced AIHA diagnosed. The woman started receiving secukinumab at a half dose again in December 2018. Following two months of rechallenge, her haemoglobin concentration was found to be depleted. Tests were repeated and confirmed the recurrence of AIHA. Secukinumab was discontinued, and in May 2019, her haemoglobin concentration increased up to 140 g/L. As per Naranjo ADR probability scale, the AIHA and secukinumab were probably related. Rivas S, et al. Secukinumab-Induced Acute Autoimmune Hemolytic Anemia. Annals of Pharmacotherapy 54: 933-934, No. 9, Sep 2020. Available from: URL: http:// 803499624 doi.org/10.1177/1060028020907202
0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Sep 2020 No. 1820
Data Loading...
